GOSS
Price:
$0.7009
Market Cap:
$158.83M
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system ...[Read more]
Industry
Biotechnology
IPO Date
2019-02-08
Stock Exchange
NASDAQ
Ticker
GOSS
According to Gossamer Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -127.28%. This represents a change of 121.24% compared to the average of -57.53% of the last 4 quarters.
The mean historical ROE of Gossamer Bio, Inc. over the last ten years is 19.21%. The current -127.28% ROE has changed -762.42% with respect to the historical average. Over the past ten years (40 quarters), GOSS's ROE was at its highest in in the March 2018 quarter at 379.44%. The ROE was at its lowest in in the March 2022 quarter at -203.01%.
Average
19.21%
Median
48.84%
Minimum
-286.47%
Maximum
122.40%
Discovering the peaks and valleys of Gossamer Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 46.23%
Maximum Annual ROE = 122.40%
Minimum Annual Increase = -1330.94%
Minimum Annual ROE = -286.47%
Year | ROE | Change |
---|---|---|
2023 | -286.47% | -1330.94% |
2022 | 23.27% | -24.17% |
2021 | 30.69% | -29.54% |
2020 | 43.56% | -19.49% |
2019 | 54.11% | -55.79% |
2018 | 122.40% | 24.05% |
2017 | 98.67% | 46.23% |
The current ROE of Gossamer Bio, Inc. (GOSS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-77.50%
5-year avg
-26.97%
10-year avg
19.21%
Gossamer Bio, Inc.’s ROE is greater than Biomea Fusion, Inc. (-118.90%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Homology Medicines, Inc. (-100.91%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvectis Pharma, Inc. (-155.80%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Kronos Bio, Inc. (-64.55%), greater than Passage Bio, Inc. (-72.53%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than TCR2 Therapeutics Inc. (-71.90%), greater than Harpoon Therapeutics, Inc. (-19.66%), greater than Alector, Inc. (-108.77%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Inozyme Pharma, Inc. (-88.42%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Atreca, Inc. (-199.88%), greater than 4D Molecular Therapeutics, Inc. (-28.00%),
Company | ROE | Market cap |
---|---|---|
-118.90% | $242.80M | |
-54.45% | $678.51M | |
-32.52% | $2.16B | |
-100.91% | $3.02M | |
-53.12% | $992.23M | |
-155.80% | $93.13M | |
-178.68% | $13.94M | |
-64.55% | $56.73M | |
-72.53% | $46.23M | |
-68.08% | $139.20M | |
-71.90% | $58.11M | |
-19.66% | $865.08M | |
-108.77% | $214.47M | |
-32.76% | $601.37M | |
-85.39% | $360.56M | |
-32.99% | $135.78M | |
-88.42% | $172.81M | |
-32.51% | $65.23M | |
-199.88% | $3.57M | |
-28.00% | $330.07M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gossamer Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gossamer Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Gossamer Bio, Inc.'s ROE?
How is the ROE calculated for Gossamer Bio, Inc. (GOSS)?
What is the highest ROE for Gossamer Bio, Inc. (GOSS)?
What is the 3-year average ROE for Gossamer Bio, Inc. (GOSS)?
What is the 5-year average ROE for Gossamer Bio, Inc. (GOSS)?
How does the current ROE for Gossamer Bio, Inc. (GOSS) compare to its historical average?